Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Endogenous opioid peptides and prescription opioid drugs modulate pain, anxiety and stress by activating four classical opioid receptors (MOR, DOR, KOR and NOP). The laboratory of Immuno-Pharmacology and Interactomics has recently identified a new broad-spectrum opioid receptor: ACKR3/CXCR7, hitherto known as atypical scavenger receptor for chemokines. In contrast to classical opioid receptors, ACKR3 is a non-signalling receptor with unique scavenging functions for opioid peptides produced in the central nervous system, reducing their availability and signalling through the classical opioid receptors. The expansion of the opioid receptor family by a new non-signalling member with original regulatory functions adds an unforeseen dimension of fine-tuning to the opioid system but also opens promising alternative strategies for therapeutic intervention in opioid-related disorders, which is particularly timely in the context of the opioid crisis. However, it is now necessary to better understand the multidimensional regulatory roles that ACKR3 exerts on the opioid network.
Michel Bouvier
Université du Luxembourg
Life Sciences
Education
Université de Montréal
Globalink Research Award
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.